Free Alerts   Login
Health Care › Pharmaceutical Preparations

NGM Stock Price Correlated With NGM Biopharmaceuticals Financials

NGM Stock Price vs. Quarterly
NGM
Income Statement
Cash Flow
Balance Sheet

NGM Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

NGM Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

NGM Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Column Group
18,136,735 sh
 
$15,579
Blackrock.
3,178,165 sh
-661,714 sh
-17%
$2,730
-$1,377
Vanguard Group
2,770,574 sh
9,472 sh
0%
$2,380
-$575
Ecor1 Capital
2,385,873 sh
-4,049,645 sh
-63%
$2,049
-$14,619
Stepstone Group Lp
1,573,357 sh
 
$1,352
Acadian Asset Management
1,339,331 sh
145,360 sh
12%
$1
Millennium Management
1,262,395 sh
1,051,272 sh
498%
$1,084
$858
Euclidean Capital
992,168 sh
 
$852
Geode Capital Management
921,610 sh
34,709 sh
4%
$792
-$157
State Street
822,399 sh
27,876 sh
4%
$706
-$144
Renaissance Technologies
756,892 sh
234,565 sh
45%
$1
Nuveen Asset Management
624,532 sh
742 sh
0%
$536
-$131
Two Sigma Advisers, Lp
586,900 sh
112,900 sh
24%
$504
-$3
Jacobs Levy Equity Management
555,826 sh
-2,778 sh
0%
$477
-$121
Two Sigma Investments, Lp
490,516 sh
83,688 sh
21%
$421
-$14
Federated Hermes.
345,381 sh
-240,208 sh
-41%
$297
-$330
Northernrp
337,282 sh
-6,789 sh
-2%
$289
-$79
Gsa Capital Partners
334,473 sh
120,797 sh
57%
$287
$58
D. E. Shaw & Co..
308,104 sh
-14,368 sh
-4%
$265
-$80
Charles Schwab Investment Management
278,704 sh
3,640 sh
1%
$239
-$55
COMPANY PROFILE
Organization and Description of BusinessNGM Biopharmaceuticals, Inc. and its wholly-owned subsidiary, NGM Biopharmaceuticals Australia Pty Ltd., collectively referred to as the Company, is focused on discovering and developing novel, potentially life-changing medicines based on scientific understanding of key biological pathways underlying cancer, retinal diseases and liver and metabolic diseases. The Company’s robust portfolio of product candidates range from early discovery to Phase 2b development and include NGM707, NGM831, NGM438, NGM120, NGM621, aldafermin and MK-3655. The Company has additional undisclosed programs that are in various stages of development ranging from functional validation to preclinical development.The Company was incorporated in Delaware in December 2007 and commenced operations in 2008. The Company's headquarters are located at 333 Oyster Point Blvd., South San Francisco, California 94080.

Free historical financial statements for NGM Biopharmaceuticals Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 20 quarters since 2019. Compare with NGM stock chart to see long term trends.

Data imported from NGM Biopharmaceuticals Inc. SEC filings. Check original filings before making any investment decision.